Biogen's Anticipated Alzheimer's Drug Is Still Months Away

Biogen's planned submission of its Alzheimer's drug, aducanumab, to the U.S. Food and Drug Administration early this year has been hit with delays, with the latest disclosure indicating that the company plans to submit the application in the third quarter, reports Quartz . Biogen's decision to cancel aducanumab trials on account of insignificant effects, and then restart them following a reconsideration of the initial data, has already sowed doubt. Repeated queries from analysts have yielded little clarity from the drugmaker on the reason for the delayed submission. "Nothing has come up with the data that has changed our interpretation," insisted Biogen's Al Sandrock. He added that the coronavirus' effect on Biogen's employees, many of whom contracted and spread the virus at the company's annual leadership meeting in March, played a part in the delay. Biogen announced that it was planning to continue the "vast majority" of the clinical trials showcased last year, and would have to resort to remote monitoring, telemedicine, and intravenous home infusions to continue testing safely.